Securities class actions are on the rise and life sciences organizations are of specific interest to regulators. In our sixth episode of BioDech, a global life sciences broadcast series, Joni Jacobsen, co-chair of the global securities and complex litigation team and Angela Liu, securities litigation partner are joined by Tiffany Engsell, Senior Counsel, Litigation & Government Investigations, Bristol Myers Squibb, to discuss securities fraud class actions against U.S. life sciences companies and what to look out for after your company becomes public.

Executive compensation plays a critical role in preparing for a successful IPO. In the fifth episode of BioDech, a global life sciences broadcast series, Kevin Kay, partner in Dechert's Employee Benefits and Executive Compensation practice, is joined by guest speakers John Schultz, Managing Director and co-head of the Compensation and Benefits practice at Alvarez & Marsal, and Brennan Rittenhouse, Managing Director at Alvarez & Marsal, to discuss understanding the market, identifying your organization’s peer groups, designing competitive compensation components, and other regulatory and disclosure requirements. 

Cybersecurity is the number one topic that keeps boards and executives up at night. Threats of all kinds – from nation states to organized crime – are eager to steal the most valuable information and hold your company ransom, among other cyber threats. 

In our fourth episode of BioDech, Brenda Sharton, partner and Chair of Dechert’s top ranked, global Privacy & Cybersecurity practice, and Sophie Pelé, a Life Sciences Regulatory partner, are joined by guest speakers John Ansbach, Managing Director, Engagement Management at Stroz Friedberg, and Zoe Philippides, SVP, Chief Ethics, Compliance & Privacy Officer & Global Head of Litigation at Moderna to discuss major developments on the threat landscape, how to proactively respond to any potential threats, and how to ensure your company’s cybersecurity preparations can withstand the scrutiny of due diligence, especially when readying itself for an IPO. 

In the third episode of BioDech,  a global life sciences broadcast series, Jolie Siegel, Chief Legal Officer of C4 Therapeutics, Inc., and Marco Taglietti, M.D., Independent Board Director of Aquestive Therapeutics, join Dechert's John Alessi and Stephen Leitzell to discuss corporate governance considerations leading up to an IPO, including board composition, financial controls and overall risk management, and forward-looking concerns for newly public companies.

Learn more.

In our second episode of BioDech,  a global life sciences broadcast series, David Rosenthal, corporate and securities partner and co-lead of the firm's life sciences practice, is joined by guest speakers Gregg Beloff, co-founder and managing director of Danforth Advisors, Gabe Cavazos, senior managing director in investment banking at SVB Securities, and Mark Hahn, CFO of Verona Pharma, to discuss the process of selecting an investment bank for an IPO.

Learn more.

As a biotech company, how do you determine when you are ready to go public? Our inaugural episode of BioDech, a global life sciences broadcast series, features guest speaker Philip Ross, global chairman of J.P. Morgan Investment Banking, and Dechert's Anna Tomczyk and Gregory Schernecke, partners in the firm's corporate and life sciences practices. 

Learn more.